ALUMIS INC.

Profile

Company Names

ALUMIS INC.
FL2021-001, INC.

Addresses

280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA 94080

601 CALIFORNIA STREET, SUITE 600, SAN FRANCISCO, CA 94108

Phone Numbers

650-231-6625
4157876009

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, OTHER HEALTH CARE

Year Incorporated:

2021

State Incorporated:

DELAWARE

Total Amount Raised:

$239,999,957.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2024-07-17 
$40,000,000.00 
$40,000,000.00 
$0.00 
Equity 
3
2024-03-04 
$129,499,957.00 
$258,999,914.00 
$129,499,957.00 
Equity 
2
2021-03-04 
$60,000,000.00 
$60,000,000.00 
$0.00 
Equity, Debt 
1
2021-02-12 
$10,500,000.00 
$10,500,000.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
SRINIVAS 
 
AKKARAJU 
DIRECTOR
SEATTLE GENETICS INC /WA   |  PRESIDIO PHARMACEUTICALS, INC.   |  VERSARTIS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  SYROS PHARMACEUTICALS, INC.   |  SAMSARA BIOCAPITAL, L.P.   |  565 SPV I, L.P.   |  TENTARIX BIOTHERAPEUTICS, LP   |  CHINOOK THERAPEUTICS U.S., INC.   |  MINERALYS THERAPEUTICS, INC.   |  ORSOBIO, INC.   |  VTV THERAPEUTICS INC.   |  ALUMIS INC.   |  SAMSARA OPPORTUNITY FUND, L.P.
MARTIN 
 
BABLER 
EXECUTIVE OFFICER, DIRECTOR
INFINITY PHARMACEUTICALS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  ALUMIS INC.
VIKRAM 
 
BAJAJ 
DIRECTOR
INTERLINE THERAPEUTICS, INC.   |  FL2021-001, INC.   |  FL2020-004, INC.   |  SPEAR BIO INC.
JULIAN 
 
BAKER 
DIRECTOR
ALUMIS INC.   |  BAKER BROTHERS LIFE SCIENCES LP   |  HCIF OFFSHORE LP
MARK 
 
BRADLEY 
EXECUTIVE OFFICER
PLAYERS NETWORK   |  ILS ORION FUND LTD.   |  ENDO, INC.   |  ALUMIS INC.
ALAN 
 
COLOWICK 
DIRECTOR
NORA THERAPEUTICS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  VELOSBIO INC.   |  INCARDA THERAPEUTICS, INC.   |  SOLVE THERAPEUTICS, INC.   |  RECODE THERAPEUTICS, INC.   |  ANUMANA, INC.   |  HARPOON THERAPEUTICS, INC.   |  ALUMIS INC.
ALAN 
B. 
COLOWICK 
DIRECTOR
GLOUCESTER PHARMACEUTICALS INC   |  ACHAOGEN INC   |  ALUMIS INC.
JORN 
 
DRAPPA 
EXECUTIVE OFFICER
ALUMIS INC.
RICHARD 
 
GASTER 
DIRECTOR
ARRAKIS THERAPEUTICS, INC.   |  AEOVIAN PHARMACEUTICALS, INC.   |  STARGAZER PHARMACEUTICALS, INC.   |  ELEVATION ONCOLOGY, INC.   |  VENBIO GLOBAL STRATEGIC FUND IV, L.P.   |  ATTRALUS, INC.   |  VENTYX BIOSCIENCES, INC.   |  ALUMIS INC.   |  ENTACT BIO, INC.   |  VENBIO GLOBAL STRATEGIC FUND V, L.P.
DAVID 
M. 
GOLDSTEIN 
EXECUTIVE OFFICER
ALUMIS INC.
ROY 
C. 
HARDIMAN 
EXECUTIVE OFFICER
ALUMIS INC.
SARA 
 
KLEIN 
EXECUTIVE OFFICER
ALUMIS INC.
JUNE 
 
LEE 
EXECUTIVE OFFICER, DIRECTOR
FL2021-001, INC.   |  ELEDON PHARMACEUTICALS, INC.   |  RENASANT BIO, INC.
PATRICK 
 
MACHADO 
DIRECTOR
TURNSTONE BIOLOGICS CORP.   |  CHIMERIX INC   |  ADVERUM BIOTECHNOLOGIES, INC.   |  ALUMIS INC.   |  AVENZO THERAPEUTICS, INC.
DERRICK 
 
RICHARDSON 
EXECUTIVE OFFICER
ALUMIS INC.
MICHAEL 
 
ROME 
DIRECTOR
SEAVIEW CAPITAL PARTNERS LP   |  SEAVIEW OFFSHORE FUND LTD.   |  ROME CAPITAL INVESTORS OFFSHORE LTD.   |  THESEUS PHARMACEUTICALS, INC.   |  FL2021-001, INC.   |  AVENZO THERAPEUTICS, INC.   |  REMIX THERAPEUTICS, INC.
JOHN 
R. 
SCHROER 
EXECUTIVE OFFICER
TRANSLATE BIO, INC.   |  ALUMIS INC.
SAPNA 
 
SRIVASTAVA 
DIRECTOR
MYOS CORP   |  ASCLEPIX THERAPEUTICS, INC.   |  EGENESIS, INC.   |  ALUMIS INC.
SAPNA 
B. 
SRIVASTAVA 
DIRECTOR
ALUMIS INC.
JAMES 
 
TANANBAUM 
DIRECTOR
VITAE PHARMACEUTICALS, INC   |  TARSA THERAPEUTICS, INC.   |  WAVETEC VISION SYSTEMS INC   |  ALLERGEN RESEARCH CORP   |  FULCRUM THERAPEUTICS, INC.   |  INTERLINE THERAPEUTICS, INC.   |  FL2021-001, INC.   |  EIKON THERAPEUTICS, INC.   |  FL2020-004, INC.   |  FORESITE CAPITAL FUND VI LP   |  FORESITE CAPITAL FUND VI (FEEDER), LP   |  ALUMIS INC.
JAMES 
B. 
TANANBAUM 
DIRECTOR
JAZZ PHARMACEUTICALS INC   |  PATHWORK DIAGNOSTICS INC   |  FORESITE CAPITAL II-AA, LLC   |  FORESITE CAPITAL IV-C, LLC   |  FORESITE CAPITAL FUND II, L.P.   |  PARDES BIOSCIENCES, INC   |  ALUMIS INC.
ZHENGBIN 
 
YAO 
DIRECTOR
NIKANG THERAPEUTICS, INC.   |  ALUMIS INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-07-24
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2024-07-17 
2024-03-11
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2024-03-04 
2021-03-19
D
Link
OTHER HEALTH CARE 
 
DECLINE TO DISCLOSE 
Equity, Debt 
2021-03-04 
2021-02-25
D
Link
OTHER HEALTH CARE 
 
DECLINE TO DISCLOSE 
Equity 
2021-02-12 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#